Advertisement
Screener

ZAI LAB LIMITED (ZLAB) Operating Income

ZAI LAB LIMITED Operating Income

ZAI LAB LIMITED (ZLAB) reported Operating Income of -$76.49 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Income Statement

us-gaap:OperatingIncomeLoss · last filed 2026-08-06

  • ZAI LAB LIMITED operating income (loss) for the quarter ending 2026-06-30 was -$76.49M.
  • ZAI LAB LIMITED operating income (loss) for the quarter ending 2026-03-31 was -$69.39M.
  • ZAI LAB LIMITED operating income (loss) for the quarter ending 2025-12-31 was -$69.41M.
  • ZAI LAB LIMITED operating income (loss) for the quarter ending 2025-09-30 was -$48.82M.
  • ZAI LAB LIMITED operating income (loss) for fiscal 2025 was -$229.43M.
  • ZAI LAB LIMITED operating income (loss) for fiscal 2024 was -$282.12M.
  • ZAI LAB LIMITED operating income (loss) for fiscal 2023 was -$366.57M.
  • ZAI LAB LIMITED operating income (loss) for fiscal 2022 was -$404.36M.
Period endOperating Income (Loss) 3 monthOperating Income (Loss) 6 monthOperating Income (Loss) 9 monthOperating Income (Loss) 12 monthOperating Income (Loss) 12 month as first filed
2026-06-30-$76.49M
10-Q · filed 2026-08-06
-$145.87M
10-Q · filed 2026-08-06
-$215.28M
derived: sum of 3 quarters · filed 2026-08-06
-$264.10M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31-$69.39M
10-Q · filed 2026-05-07
-$138.79M
derived: sum of 2 quarters · filed 2026-05-07
-$187.61M
derived: sum of 3 quarters · filed 2026-05-07
-$242.51M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31-$69.41M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$118.23M
derived: sum of 2 quarters · filed 2026-02-26
-$173.12M
derived: sum of 3 quarters · filed 2026-08-06
-$229.43M
10-K · filed 2026-02-26
2025-09-30-$48.82M
10-Q · filed 2025-11-06
-$103.72M
derived: sum of 2 quarters · filed 2026-08-06
-$160.03M
10-Q · filed 2025-11-06
-$227.92M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30-$54.90M
10-Q · filed 2026-08-06
-$111.21M
10-Q · filed 2026-08-06
-$179.10M
derived: sum of 3 quarters · filed 2026-08-06
-$246.95M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31-$56.31M
10-Q · filed 2026-05-07
-$124.20M
derived: sum of 2 quarters · filed 2026-05-07
-$192.06M
derived: sum of 3 quarters · filed 2026-05-07
-$268.12M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31-$67.89M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$135.74M
derived: sum of 2 quarters · filed 2026-02-26
-$211.81M
derived: sum of 3 quarters · filed 2026-02-26
-$282.12M
10-K · filed 2026-02-26
2024-09-30-$67.85M
10-Q · filed 2025-11-06
-$143.92M
derived: sum of 2 quarters · filed 2025-11-06
-$214.23M
10-Q · filed 2025-11-06
-$338.21M
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30-$76.06M
10-Q · filed 2025-08-07
-$146.37M
10-Q · filed 2025-08-07
-$270.35M
derived: sum of 3 quarters · filed 2026-02-26
-$353.92M
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31-$70.31M
10-Q · filed 2025-05-08
-$194.29M
derived: sum of 2 quarters · filed 2026-02-26
-$277.86M
derived: sum of 3 quarters · filed 2026-02-26
-$367.36M
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31-$123.98M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$207.55M
derived: sum of 2 quarters · filed 2026-02-26
-$297.05M
derived: sum of 3 quarters · filed 2026-02-26
-$366.57M
10-K · filed 2026-02-26
2023-09-30-$83.57M
10-Q · filed 2024-11-12
-$173.07M
derived: sum of 2 quarters · filed 2024-11-12
-$242.59M
10-Q · filed 2024-11-12
-$339.89M
derived: sum of 4 quarters · filed 2025-02-27
2023-06-30-$89.50M
10-Q · filed 2024-08-06
-$159.02M
10-Q · filed 2024-08-06
-$256.32M
derived: sum of 3 quarters · filed 2025-02-27
-$384.90M
derived: sum of 4 quarters · filed 2025-02-27
2023-03-31-$69.52M
10-Q · filed 2024-05-08
-$166.81M
derived: sum of 2 quarters · filed 2025-02-27
-$295.40M
derived: sum of 3 quarters · filed 2025-02-27
-$394.11M
derived: sum of 4 quarters · filed 2025-02-27
2022-12-31-$97.29M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27
-$225.88M
derived: sum of 2 quarters · filed 2025-02-27
-$324.59M
derived: sum of 3 quarters · filed 2025-02-27
-$404.36M
10-K · filed 2025-02-27
2022-09-30-$128.58M
10-Q · filed 2023-11-07
-$227.30M
derived: sum of 2 quarters · filed 2023-11-07
-$307.06M
10-Q · filed 2023-11-07
-$526.26M
derived: sum of 4 quarters · filed 2023-11-07
2022-06-30-$98.72M
10-Q · filed 2023-08-07
-$178.48M
10-Q · filed 2023-08-07
-$397.68M
derived: sum of 3 quarters · filed 2023-08-07
-$480.88M
derived: sum of 4 quarters · filed 2023-08-07
2022-03-31-$79.76M
10-Q · filed 2023-05-09
-$298.96M
derived: sum of 2 quarters · filed 2023-05-09
-$382.17M
derived: sum of 3 quarters · filed 2023-05-09
-$552.74M
derived: sum of 4 quarters · filed 2023-05-09
2021-12-31-$219.20M
10-K · filed 2022-03-01
-$302.40M
derived: sum of 2 quarters · filed 2022-11-09
-$472.97M
derived: sum of 3 quarters · filed 2022-11-09
-$700.06M
10-K · filed 2024-02-27
2021-09-30-$83.20M
10-Q · filed 2022-11-09
-$253.78M
derived: sum of 2 quarters · filed 2022-11-09
-$480.87M
10-Q · filed 2022-11-09
-$576.12M
derived: sum of 4 quarters · filed 2022-11-09
2021-06-30-$170.57M
10-Q · filed 2022-08-09
-$397.66M
10-Q · filed 2022-08-09
-$492.92M
derived: sum of 3 quarters · filed 2022-08-09
-$569.18M
derived: sum of 4 quarters · filed 2022-08-09
2021-03-31-$227.09M
10-Q · filed 2022-05-10
-$322.35M
derived: sum of 2 quarters · filed 2022-05-10
-$398.61M
derived: sum of 3 quarters · filed 2022-05-10
-$482.57M
derived: sum of 4 quarters · filed 2022-05-10
2020-12-31-$95.26M
10-K · filed 2022-03-01
-$171.51M
derived: sum of 2 quarters · filed 2022-03-01
-$255.48M
derived: sum of 3 quarters · filed 2022-03-01
-$301.80M
10-K · filed 2023-03-01
2020-09-30-$76.26M
10-K · filed 2022-03-01
-$160.22M
derived: sum of 2 quarters · filed 2022-03-01
-$206.54M
10-Q · filed 2021-11-09
-$258.59M
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30-$83.97M
10-K · filed 2022-03-01
-$130.29M
10-Q · filed 2021-08-09
-$182.34M
derived: sum of 3 quarters · filed 2022-03-01
-$247.60M
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31-$46.32M
10-K · filed 2022-03-01
-$98.37M
derived: sum of 2 quarters · filed 2022-03-01
-$163.64M
derived: sum of 3 quarters · filed 2022-03-01
2019-12-31-$52.05M
derived: 10-K 12 month − 6-K 9 month · filed 2022-03-01
-$117.32M
derived: sum of 2 quarters · filed 2022-03-01
-$203.20M
10-K · filed 2022-03-01
2019-09-30-$65.27M
derived: 6-K 9 month − 6-K 6 month · filed 2020-01-21
-$151.15M
6-K · filed 2020-01-21
2019-06-30-$85.88M
6-K · filed 2020-09-11
2018-12-31-$66.54M
derived: 10-K 12 month − 6-K 9 month · filed 2021-03-01
-$141.77M
10-K · filed 2021-03-01
-$141.77M
20-F · filed 2019-03-29
2018-09-30-$75.22M
6-K · filed 2020-01-21
2017-12-31-$51.39M
20-F · filed 2020-04-29
-$51.39M
20-F · filed 2018-04-30
2016-12-31-$38.53M
20-F · filed 2019-03-29
2015-12-31-$16.35M
20-F · filed 2018-04-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aurinia Pharmaceuticals Inc. (AUPH)$2.207B7.18
Prestige Consumer Healthcare Inc. (PBH)United States$2.163B13.03
OCULAR THERAPEUTIX, INC (OCUL)United States$2.159B-7.15
Viridian Therapeutics, Inc.\DE (VRDN)United States$2.342B-5.38
Mineralys Therapeutics, Inc. (MLYS)United States$2.353B-6.82
Bausch Health Companies Inc. (BHC)$2.113B-1.68
Braveheart Bio, Inc. (BRVE)United States$2.106B
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
Harmony Biosciences Holdings, Inc. (HRMY)United States$2.399B11.67